HIV infection and older Americans: The public health perspective

American Journal of Public Health

Volumn 102, Issue 8, 2012, Pages 1516-1526

  Brooks, John T ^a   Buchacz, Kate ^a   Gebo, Kelly A ^b   Mermin, Jonathan ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ELDERLY CARE; HEALTH PROMOTION; HEALTH SERVICE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIDDLE AGED; NEEDS ASSESSMENT; ORGANIZATION AND MANAGEMENT; PUBLIC HEALTH; REVIEW; RISK FACTOR; UNITED STATES;

AGED; HEALTH PROMOTION; HEALTH SERVICES FOR THE AGED; HEALTH SERVICES NEEDS AND DEMAND; HIV; HIV INFECTIONS; HUMANS; MIDDLE AGED; NEEDS ASSESSMENT; PUBLIC HEALTH; RISK FACTORS; UNITED STATES;

EID: 84864332264     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2012.300844     Document Type: Review

References (113)

1. Prejean J, Song R, Hernandez A, et al. Estimated HIV incidence in the United States, 2006-2009. PLoS ONE. 2011;6(8):e17502.
2. Centers for Disease Control and Prevention. HIV Surveillance Report, 2010, Vol. 22. Published March 2012. Available at: http://www.cdc.gov/hiv/ topics/ surveillance/resources/reports. Accessed May 25, 2012.
3. el-Sadr W, Gettler J. Unrecognized human immunodeficiency virus infection in the elderly. Arch Intern Med. 1995;155(2):184-186.
4. Lindau ST, Schumm LP, Laumann EO, Levinson W, O'Muircheartaigh CA, Waite LJ. A study of sexuality and health among older adults in the United States. N Engl J Med. 2007;357(8):762-774. (Pubitemid 47295643)
5. Onen NF, Shacham E, Stamm KE, Overton ET. Comparisons of sexual behaviors and STD prevalence among older and younger individuals with HIV infection. AIDS Care. 2010;22(6):711-717.
6. Levy JA, Ory MG, Crystal S. HIV/AIDS interventions for midlife and older adults: current status and challenges. J Acquir Immune Defic Syndr. 2003;33(Suppl 2): S59-S67. (Pubitemid 36801603)
7. Savasta AM. HIV: associated transmission risks in older adults-an integrative review of the literature. J Assoc Nurses AIDS Care. 2004;15(1):50-59. (Pubitemid 38552973)
8. Henderson SJ, Bernstein LB, George DM, Doyle JP, Paranjape AS, Corbie-Smith G. Older women and HIV: how much do they know and where are they getting their information? J Am Geriatr Soc. 2004;52(9):1549-1553. (Pubitemid 39209606)
9. Loeb DF, Lee RS, Binswanger IA, Ellison MC, Aagaard EM. Patient, resident physician, and visit factors associated with documentation of sexual history in the outpatient setting. J Gen Intern Med. 2011;26(8):887-893.
10. Schick V, Herbenick D, Reece M, et al. Sexual behaviors, condom use, and sexual health of Americans over 50: implications for sexual health promotion for older adults. J Sex Med. 2010;7(Suppl 5):315-329.
11. Lindau ST, Leitsch SA, Lundberg KL, Jerome J. Older women's attitudes, behavior, and communication about sex and HIV: a community-based study. JWomens Health (Larchmt). 2006;15(6):747-753. (Pubitemid 44349852)
12. Meditz A, Moreau K, MaWhinney S, et al. CCR5 expression is elevated on endocervical CD4+ T cells in healthy postmenopausal women. J Acquir Immune Defic Syndr. 2012;59(3):221-228.
13. Rollenhagen C, Asin S. Enhanced HIV-1 replication in ex vivo ectocervical tissues from post-menopausal women correlates with increased inflammatory responses. Mucosal Immunol. 2011;4(6):671-681.
14. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR-14):1-17.
15. Sanders GD, Bayoumi AM, Holodnly M, Owens DK. Cost-effectiveness ofHIV screening in patients older than 55 years of age. Ann Intern Med. 2008;148(12):889-903. (Pubitemid 351860821)
16. Paltiel AD, Weinstein MC, Kimmel AD, et al. Expanded screening for HIV in the United States-an analysis of cost-effectiveness. N Engl J Med. 2005;352 (6):586-595. (Pubitemid 40204671)
17. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587- 2599.
18. Smith DK, Grant RM, Weidle PJ, Lansky A, Mermin J, Fenton KA. Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men [Reprinted from MMWR Morb Mortal Wkly Rep. 2011;60:65-68]. JAMA. 2011;305(11): 1089-1091.
19. Tabnak F, Sun R. Need for HIV/AIDS early identification and preventive measures among middleaged and elderly women. Am J Public Health. 2000;90 (2):287-288. (Pubitemid 30062686)
20. Gay Men's Health Crisis. Growing Older With the Epidemic: HIV and Aging. 2010. Available at: http:// www.gmhc.org/files/editor/file/a-pa-aging10-emb2. pdf. Accessed May 25, 2012.
21. National Alliance of State and Territorial AIDS Directors and the Kaiser Family Foundation. The National HIV Prevention Inventory: The State of HIV Prevention Across the U.S. 2009. Available at: http://www. nastad.org/Docs/ highlight/2010313-NASTAD%20 Prevention%20Inventory%20-%20REVISED.pdf. Accessed May 25, 2012.
22. Agate LL, Mullins JM, Prudent ES, Liberti TM. Strategies for reaching retirement communities and aging social networks: HIV/AIDS prevention activities among seniors in South Florida. J Acquir Immune Defic Syndr. 2003;33(Suppl 2):S238-S242. (Pubitemid 36801625)
23. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372(9635):293-299.
24. Losina E, Schackman BR, Sadownik SN, et al. Racial and sex disparities in life expectancy losses among HIV-infected persons in the United States: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis. 2009;49(10): 1570-1578.
25. Nakagawa F, Lodwick RK, Smith CJ, et al. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS. 2012;26(3):335-343.
26. Linley L, Prejean J, Ann Q, Chen M, Hall HI. Racial/ ethnic disparities in HIV diagnoses among persons aged 50 years and older in 37 US states, 2005-2008. Am J Public Health. 2012;102(8):1527-1534.
27. Advancing HIV prevention: new strategies for a changing epidemic-United States, 2003. Ann Pharmacother. 2003;37(6):935.
28. Hall HI, Espinoza L, Benbow N, Hu YYW, Urban Areas HIV Surveillance Workgroup. Epidemiology of HIV infection in large urban areas in the United States. PLoS ONE. 2010;5(9):e12756.
29. Bhaskaran K, Hamouda O, Sannes M, et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA. 2008; 300(1):51-59. (Pubitemid 351920404)
30. May M, Sterne JA, Sabin C, et al. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS. 2007;21(9):1185-1197. (Pubitemid 46763289)
31. Ewings FM, Bhaskaran K, McLean K, et al. Survival following HIV infection of a cohort followed up from seroconversion in the UK. AIDS. 2008;22(1):89-95. (Pubitemid 350294882)
32. Harrison KM, Song RG, Zhang XJ. Life expectancy after HIV diagnosis based on national HIV surveillance data from 25 states, United States. J Acquir Immune Defic Syndr. 2010;53(1):124-130.
33. Althoff KN, Gebo KA, Gange SJ, et al. CD4 count at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation? AIDS Res Ther. 2010;7:45.
34. Department of Health and Human Services, Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents-March 27, 2012. Available at: http://aidsinfo.nih.gov/ContentFiles/Adultand AdolescentGL.pdf. Accessed May 25, 2012.
35. Silverberg MJ, Leyden W, Horberg MA, DeLorenze GN, Klein D, Quesenberry CP Jr. Older age and the response to and tolerability of antiretroviral therapy. Arch Intern Med. 2007;167(7):684-691. (Pubitemid 46598461)
36. Althoff KN, Justice AC, Gange SJ, et al. Virologic and immunologic response to HAART, by age and regimen class. AIDS. 2010;24(16):2469-2479.
37. Sabin CA, Smith CJ, Delpech V, et al. The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapy. HIV Med. 2009;10(1): 35-43.
38. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010;304(3):321-333.
39. Onen NF, Overton ET, Seyfried W, et al. Aging and HIV infection: a comparison between older HIV-infected persons and the general population. HIV Clin Trials. 2010;11(2):100-109.
40. Goulet JL, Fultz SL, Rimland D, et al. Do patterns of comorbidity vary by HIV status, age, and HIV severity? Clin Infect Dis. 2007;45(12):1593-1601. (Pubitemid 351411845)
41. Adih WK, Selik RM, Xiaohong H. Trends in diseases reported on US death certificates that mentioned HIV infection, 1996-2006. J Int Assoc Physicians AIDS Care (Chic). 2011;10(1):5-11.
42. Hasse B, Ledergerber B, Egger M, et al. Aging and non-HIV associated co-morbidity in HIV+ persons: the SHCS. Abstract 792 presented at: 18th Conference on Retroviruses and Opportunistic Infections; Boston, MA; February 27 to March 3, 2011.
43. Young B, Dao CN, Buchacz K, Baker R, Brooks JT. Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000-2006. Clin Infect Dis. 2011;52(8):1061- 1068.
44. Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med. 2006;145(6):397-406. (Pubitemid 46768570)
45. Martinez E, Milinkovic A, Buira E, et al. Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area. HIV Med. 2007;8(4):251-258. (Pubitemid 46695372)
46. Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43(1):27-34. (Pubitemid 44306484)
47. Smit C, Geskus R, Walker S, et al. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS. 2006;20(5):741-749. (Pubitemid 43884302)
48. Deeks SG. Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy. Top HIV Med. 2009;17(4):118-123.
49. Ho JE, Deeks SG, Hecht FM, et al. Initiation of antiretroviral therapy at higher nadir CD4(+) T-cell counts is associated with reduced arterial stiffness in HIVinfected individuals. AIDS. 2010;24(12):1897-1905.
50. Ferry T, Raffi F, Collin-Filleul F, et al. Uncontrolled viral replication as a risk factor for non-AIDS severe clinical events in HIV-infected patients on long-term antiretroviral therapy: APROCO/COPILOTE (ANRS CO8) Cohort Study. J Acquir Immune Defic. 2009;51 (4):407-415.
51. DallaPiazza M, Amorosa VK, Localio R, Kostman JR, Lo Re V. Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients. BMC Infect Dis. 2010;10:116.
52. Wand H, Calmy A, Carey DL, et al. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS. 2007;21(18):2445-2453. (Pubitemid 350145176)
53. Sobieszczyk ME, Hoover DR, Anastos K, et al. Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr. 2008; 48(3):272-280.
54. Hsue PY, Hunt PW, Schnell A, et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS. 2009;23 (9):1059-1067.
55. Goulet JL, Fultz SL, McGinnis KA, Justice AC. Relative prevalence of comorbidities and treatment contraindications in HIV-mono-infected and HIV/ HCV-co-infected veterans. AIDS. 2005;19(Suppl 3): S99-S105. (Pubitemid 41682176)
56. Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ. 2009;338:a3172.
57. Kaplan RC, Kingsley LA, Sharrett AR, et al. Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis. 2007;45(8):1074-1081. (Pubitemid 47580361)
58. Triant VA, Meigs JB, Grinspoon SK. Association of C-reactive protein and HIV infection with acutemyocardial infarction. J Acquir Immune Defic. 2009;51(3):268-273.
59. El-Sadr WM, Grund B, Neuhaus J, et al. Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Ann Intern Med. 2008;149(5):289-299.
60. Triant VA, Josephson F, Rochester CG, et al. Adverse outcome analyses of observational data: assessing cardiovascular risk in HIV disease. Clin Infect Dis. 2012; 54(3):408-413.
61. Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356(17):1723-1735. (Pubitemid 46658704)
62. D:A:D Study Group, Sabin CA, Worm SW,Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008;371(9622):1417-1426.
63. Lichtenstein KA, Armon C, Buchacz K, et al. Low CD4(+) T cell count is a risk factor for cardiovascular disease events in the HIV Outpatient Study. Clin Infect Dis. 2010;51(4):435-447.
64. Niaura R, Shadel WG, Morrow K, Tashima K, Flanigan T, Abrams DB. Human immunodeficiency virus infection, AIDS, and smoking cessation: the time is now. Clin Infect Dis. 2000;31(3):808-812. (Pubitemid 32295508)
65. Centers for Disease Control and Prevention. CDC Health Disparities and Inequalities Report-United States, 2011, Jan 14. Report No. 1545-8636 (electronic) 0892-3787 (linking). Available at: http://www.cdc.gov/ mmwr/pdf/other/su6001.pdf. Accessed May 25, 2012.
66. Lloyd-Richardson EE, Stanton CA, Papandonatos GD, et al. Motivation and patch treatment for HIV+ smokers: a randomized controlled trial. Addiction. 2009;104(11):1891-1900.
67. Vidrine DJ, Marks RM, Arduino RC, Gritz ER. Efficacy of cell phone-delivered smoking cessation counseling for persons living with HIV/AIDS: 3-month outcomes. Nicotine Tob Res. 2012;14(1):106-110.
68. Tedaldi EM, Brooks JT, Weidle PJ, et al. Increased body mass index does not alter response to initial highly active antiretroviral therapy in HIV-1-infected patients. J Acquir Immune Defic Syndr. 2006;43(1):35-41. (Pubitemid 44306485)
69. Keithley JK, Duloy AM, Swanson B, Zeller JM. HIV infection and obesity: a review of the evidence. J Assoc Nurses AIDS Care. 2009;20(4):260-274.
70. Crum-Cianflone N, Tejidor R, Medina S, Barahona I, Ganesan A. Obesity among patients with HIV: the latest epidemic. AIDS Patient Care STDS. 2008;22(12):925-930.
71. Arnsten JH, Freeman R, Howard AA, Floris-Moore M, Lo YT, Klein RS. Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS. 2007;21(5):617-623.
72. Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large US healthcare system. J Clin Endocrinol Metab. 2008;93(9):3499-3504.
73. Sharma A, Flom PL, Weedon J, Klein RS. Prospective study of bone mineral density changes in aging men with or at risk for HIV infection. AIDS. 2010;24(15): 2337-2345.
74. Overton ET, Mondy K, Bush TJ, et al. Factors associated with low bone mineral density (BMD) in a large cohort of HIV-infected U.S. adults-baseline results from the SUN study. Poster presented at: 14th Conference on Retroviruses and Opportunistic Infections; February 26, 2007; Los Angeles, CA.
75. Womack JA, Goulet JL, Gibert C, et al. Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PLoS ONE. 2011;6(2): e17217.
76. McComsey GA, Tebas P, Shane E, et al. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis. 2010;51 (8):937-946.
77. World Health Organization.WHO Global Report on Falls Prevention in Older Age. 2007. Available at: http:// www.who.int/ageing/publications/Falls- prevention7March.pdf. Accessed May 25, 2012.
78. Shiels MS, Pfeiffer RM, Gail MH, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst. 2011;103:1-10.
79. Crum-Cianflone N, Huppler Hullisiek K, Marconi V. Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS. 2009;23(1):41-50.
80. Silverberg MJ, Chao C, Leyden WA, et al. HIV infection and the risk of cancers with and without a known infectious cause. AIDS. 2009;23(17):2337-2345.
81. Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med. 2008;148(10):728-736. (Pubitemid 351717418)
82. Shiels MS, Cole SR, Kirk GD, Poole C. A metaanalysis of the incidence of non-AIDS cancers in HIVinfected individuals. J Acquir Immune Defic Syndr. 2009; 52(5):611-622.
83. Shiels MS, Pfeiffer RM, Engels EA. Age at cancer diagnosis among persons with AIDS in the United States. Ann Intern Med. 2010;153(7):452-460.
84. Desquilbet L, Jacobson LP, Fried LP, et al. HIV-1 infection is associated with an earlier occurrence of a phenotype related to frailty. J Gerontol A Biol Sci Med Sci. 2007;62(11):1279-1286. (Pubitemid 350287617)
85. Desquilbet L, Margolick JB, Fried LP, et al. Relationship between a frailty-related phenotype and progressive deterioration of the immune system in HIV-infected men. J Acquir Immune Defic. 2009;50 (3):299-306.
86. Oursler KK, Goulet JL, Crystal S, et al. Association of age and comorbidity with physical function in HIVinfected and uninfected patients: results from the veterans aging cohort study. AIDS Patient Care STDS. 2011;25(1):13-20.
87. Onen NF, Agbebi A, Shacham E, Stamm KE, Onen AR, Overton T. Frailty among HIV-infected persons in an urban outpatient care setting. J Infect. 2009;59(5):346-352.
88. Justice AC, McGinnis KA, Atkinson JH, et al. Psychiatric and neurocognitive disorders among HIVpositive and negative veterans in care: Veterans Aging Cohort Five-Site Study. AIDS. 2004;18(Suppl 1):S49-S59. (Pubitemid 38365906)
89. Pence BW, O'Donnell JK, Gaynes BN. Falling through the cracks: the gaps between depression prevalence, diagnosis, treatment, and response in HIV care. AIDS. 2012;26(5):656-658.
90. U.S. Department of Health and Human Services. Mental Health: A Report of the Surgeon General. Rockville, MD: National Institutes of Health, National Institute of Mental Health; 1999. Available at: http://profiles.nlm. nih.gov/ps/access/NNBBHS.pdf. Accessed May 25, 2012.
91. Cohen RA, Boland R, Paul R, et al. Neurocognitive performance enhanced by highly active antiretroviral therapy in HIV-infected women. AIDS. 2001;15(3): 341-345. (Pubitemid 32163820)
92. Harezlak J, Buchthal S, Taylor M, et al. Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment. AIDS. 2011;25(5):625-633.
93. Robertson KR, Smurzynski M, Parsons TD, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS. 2007;21(14):1915-1921. (Pubitemid 47329768)
94. Horberg MA, Silverberg MJ, Hurley LB, et al. Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients. J Acquir Immune Defic Syndr. 2008;47(3):384-390. (Pubitemid 351619427)
95. Althoff KN, Gange SJ, Klein MB, et al. Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis. 2010;50(11): 1512-1520.
96. Martin J, Volberding P. HIV and premature aging: a field still in its infancy. Ann Intern Med. 2010;153 (7):477.
97. Effros RB, Fletcher CV, Gebo K, et al. Workshop on HIV infection and aging: what is known and future research directions. Clin Infect Dis. 2008;47(4):542-553.
98. Cao W, Jamieson BD, Hultin LE, Hultin PM, Effros RB, Detels R. Premature aging of T cells is associated with faster HIV-1 disease progression. J Acquir Immune Defic Syndr. 2009;50(2):137-147.
99. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12 (12):1365-1371. (Pubitemid 44924494)
100. Appay V, Almeida JR, Sauce D, Autran B, Papagno L. Accelerated immune senescence and HIV-1 infection. Exp Gerontol. 2007;42(5):432-437. (Pubitemid 46561182)
101. Rickabaugh TM, Kilpatrick RD, Hultin LE, et al. The dual impact of HIV-1 infection and aging on naive CD4(+) T-cells: additive and distinct patterns of impairment. PLoS ONE. 2011;6(1):e16459.
102. Kaplan RC, Sinclair E, Landay AL, et al. T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis. 2011;203(4):452-463.
103. Horberg MA, Aberg JA, Cheever LW, Renner P, Kaleba EO, Asch SM. Development of national and multiagency HIV care quality measures. Clin Infect Dis. 2010;51(6):732-738.
104. Aberg JA, Kaplan JE, Libman H, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2009;49(5):651-681.
105. Hessol NA, Kalinowski A, Benning L, et al. Mortality among participants in the Multicenter AIDS Cohort Study and the Women's Interagency HIV Study. Clin Infect Dis. 2007;44(2):287-294. (Pubitemid 46079997)
106. Justice AC, Zingmond DS, Gordon KS, et al. Drug toxicity, HIV progression, or comorbidity of aging: does tipranavir use increase the risk of intracranial hemorrhage? Clin Infect Dis. 2008;47(9):1226-1230.
107. Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS. 2007; 21(10):1273-1281. (Pubitemid 46883481)
108. Bowman L, Carlstedt BC, Hancock EF, Black CD. Adverse drug reaction (ADR) occurrence and evaluation in elderly inpatients. Pharmacoepidemiol Drug Saf. 1996; 5(1):9-18. (Pubitemid 26094483)
109. Egger T, Dormann H, Ahne G, et al. Identification of adverse drug reactions in geriatric inpatients using a computerised drug database. Drugs Aging. 2003;20(10): 769-776. (Pubitemid 36995253)
110. Justice AC. Prioritizing primary care in HIV: comorbidity, toxicity, and demography. Top HIV Med. 2006;14(5):159-163.
111. Izzedine H, Launay-Vacher V, Deray G. Renal tubular transporters and antiviral drugs: an update. AIDS. 2005;19(5):455-462. (Pubitemid 40515848)
112. Centers for Disease Control and Prevention. Incorporating HIV prevention into the medical care of persons living with HIV. Recommendations of CDC, the Health Resources and Services Administration, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2003;52(RR-12):1-24.
113. Buchacz K, Baker RK, Moorman AC, et al. Rates of hospitalizations and associated diagnoses in a large multisite cohort of HIV patients in the United States, 1994-2005. AIDS. 2008;22(11):1345-1354.